1. Home
  2. CAC vs MLYS Comparison

CAC vs MLYS Comparison

Compare CAC & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CAC
  • MLYS
  • Stock Information
  • Founded
  • CAC 1875
  • MLYS 2019
  • Country
  • CAC United States
  • MLYS United States
  • Employees
  • CAC N/A
  • MLYS N/A
  • Industry
  • CAC Major Banks
  • MLYS Biotechnology: Pharmaceutical Preparations
  • Sector
  • CAC Finance
  • MLYS Health Care
  • Exchange
  • CAC Nasdaq
  • MLYS Nasdaq
  • Market Cap
  • CAC N/A
  • MLYS 1.0B
  • IPO Year
  • CAC 1997
  • MLYS 2023
  • Fundamental
  • Price
  • CAC $42.28
  • MLYS $14.37
  • Analyst Decision
  • CAC Hold
  • MLYS Strong Buy
  • Analyst Count
  • CAC 3
  • MLYS 4
  • Target Price
  • CAC $47.33
  • MLYS $27.00
  • AVG Volume (30 Days)
  • CAC 70.1K
  • MLYS 846.2K
  • Earning Date
  • CAC 07-29-2025
  • MLYS 08-12-2025
  • Dividend Yield
  • CAC 3.96%
  • MLYS N/A
  • EPS Growth
  • CAC 2.54
  • MLYS N/A
  • EPS
  • CAC 3.09
  • MLYS N/A
  • Revenue
  • CAC $184,324,000.00
  • MLYS N/A
  • Revenue This Year
  • CAC $40.83
  • MLYS N/A
  • Revenue Next Year
  • CAC $5.29
  • MLYS N/A
  • P/E Ratio
  • CAC $13.75
  • MLYS N/A
  • Revenue Growth
  • CAC 13.26
  • MLYS N/A
  • 52 Week Low
  • CAC $34.53
  • MLYS $8.24
  • 52 Week High
  • CAC $50.07
  • MLYS $18.38
  • Technical
  • Relative Strength Index (RSI)
  • CAC 57.43
  • MLYS 48.90
  • Support Level
  • CAC $41.12
  • MLYS $14.16
  • Resistance Level
  • CAC $43.51
  • MLYS $15.24
  • Average True Range (ATR)
  • CAC 0.94
  • MLYS 0.68
  • MACD
  • CAC -0.05
  • MLYS 0.07
  • Stochastic Oscillator
  • CAC 66.07
  • MLYS 55.45

About MLYS Mineralys Therapeutics Inc.

Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.

Share on Social Networks: